|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received on June 2, 2006
Accepted on August 18, 2006
Molecular Diagnostics and Genetics |
1 Center for Cardiovascular Disease Prevention, Donald W. Reynolds Center for Cardiovascular Research, Leducq Center for Molecular and Genetic Epidemiology and the Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
2 Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
* To whom correspondence should be addressed. E-mail: rzee{at}rics.bwh.harvard.edu.
Background: Adiponectin (ADIPOQ) gene variations are associated with risk of cardiovascular disease in patients with diabetes. No prospective data are available, however, on the risk of atherothrombotic disorders in persons with ADIPOQ variations who do not have diabetes.
Methods: From a group of DNA samples collected at baseline in a prospective cohort of 14 916 initially healthy American men, we assessed the presence of 5 ADIPOQ genetic variants [db single-base variant (also known as db single-nucleotide polymorphism [dbSNP]): rs266729, rs182052, rs822396, rs2241766, and rs1501299] in samples from 600 Caucasian men who subsequently suffered an atherothrombotic event (incident myocardial infarction or ischemic stroke) and from 600 age- and smoking-matched Caucasian men who remained free of reported vascular disease during follow-up (controls).
Results: Genotype distributions for the variations tested were in Hardy-Weinberg equilibrium. Marker-by-marker conditional logistic regression analysis, adjusted for potential risk factors, showed an association of rs266729 [recessive: odds ratio (OR), 0.26; 95% confidence interval (CI), 0.10-0.64; P = 0.004] and rs182052 (recessive: OR, 0.40; 95% CI, 0.21-0.76; P = 0.006) with decreased risk of ischemic stroke. These findings remained significant after Bonferroni correction. Haplotype-based (constituted by rs266729, rs182052, and rs822396) conditional logistic regression analysis, adjusted for the same potential risk factors, showed an association of haplotype G-A-G (OR, 0.28; 95% CI, 0.09-0.87; P = 0.03) with decreased risk of ischemic stroke. Prespecified analysis limited to participants without baseline diabetes showed similar significant findings.
Conclusions: The present prospective investigation provides further evidence for a protective role of adiponectin gene variation in the risk of ischemic stroke that was independent of the presence of diabetes.
The following articles in journals at HighWire Press have cited this article:
![]() |
S. L. Prior, D. R. Gable, J. A. Cooper, S. C. Bain, S. J. Hurel, S. E. Humphries, and J. W. Stephens Association between the adiponectin promoter rs266729 gene variant and oxidative stress in patients with diabetes mellitus Eur. Heart J., May 2, 2009; 30(10): 1263 - 1269. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Howard and V. Feigin Advances in Population Studies 2007 Stroke, February 1, 2008; 39(2): 283 - 285. [Full Text] [PDF] |
||||
![]() |
R. Y.L. Zee and P. M Ridker Two Common Gene Variants on Chromosome 9 and Risk of Atherothrombosis Stroke, October 1, 2007; 38(10): e111 - e111. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |